BCAL Diagnostics Prepares for BREASTEST Launch in 2025

BCAL Diagnostics Limited (AU:BDX) has released an update.

BCAL Diagnostics Limited is set to launch the first phase of its BREASTEST product commercially at the Sydney Breast Clinic in early 2025, marking a significant milestone for the company. This phased approach aims to refine the product using insights from initial clinical use before expanding further across Australia. The company’s recent publication in a scientific journal underscores the innovative nature of BREASTEST, potentially enhancing breast cancer screening alongside traditional methods.

For further insights into AU:BDX stock, check out TipRanks’ Stock Analysis page.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.